| Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy Y Kobayashi, T Mitsudomi Cancer science 107 (9), 1179-1186, 2016 | 382 | 2016 |
| EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first-or third-generation TKIs Y Kobayashi, Y Togashi, Y Yatabe, H Mizuuchi, P Jangchul, C Kondo, ... Clinical cancer research 21 (23), 5305-5313, 2015 | 214 | 2015 |
| Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1) M Shimoji, S Shimizu, K Sato, K Suda, Y Kobayashi, K Tomizawa, ... Lung cancer 98, 69-75, 2016 | 163 | 2016 |
| Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth Y Kobayashi, T Mitsudomi, Y Sakao, Y Yatabe Annals of Oncology 26 (1), 156-161, 2015 | 139 | 2015 |
| Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected? Y Kobayashi, T Mitsudomi Translational lung cancer research 2 (5), 354, 2013 | 135 | 2013 |
| Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene T Fukui, Y Yatabe, Y Kobayashi, K Tomizawa, S Ito, S Hatooka, K Matsuo, ... Lung cancer 77 (2), 319-325, 2012 | 129 | 2012 |
| Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro T Fujino, Y Kobayashi, K Suda, T Koga, M Nishino, S Ohara, M Chiba, ... Journal of Thoracic Oncology 14 (10), 1753-1765, 2019 | 125 | 2019 |
| How long should small lung lesions of ground-glass opacity be followed? Y Kobayashi, T Fukui, S Ito, N Usami, S Hatooka, Y Yatabe, T Mitsudomi Journal of Thoracic Oncology 8 (3), 309-314, 2013 | 121 | 2013 |
| The association between baseline clinical–radiological characteristics and growth of pulmonary nodules with ground-glass opacity Y Kobayashi, Y Sakao, GA Deshpande, T Fukui, T Mizuno, H Kuroda, ... Lung Cancer 83 (1), 61-66, 2014 | 105 | 2014 |
| Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I … E Banno, Y Togashi, Y Nakamura, M Chiba, Y Kobayashi, H Hayashi, ... Cancer science 107 (8), 1134-1140, 2016 | 92 | 2016 |
| Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer Y Kobayashi, K Azuma, H Nagai, YH Kim, Y Togashi, Y Sesumi, M Chiba, ... Molecular cancer therapeutics 16 (2), 357-364, 2017 | 78 | 2017 |
| An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer C To, TS Beyett, J Jang, WW Feng, M Bahcall, HM Haikala, BH Shin, ... Nature cancer 3 (4), 402-417, 2022 | 71 | 2022 |
| Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study T Koga, Y Kobayashi, K Tomizawa, K Suda, T Kosaka, Y Sesumi, T Fujino, ... Lung Cancer 126, 72-79, 2018 | 70 | 2018 |
| Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights Y Kobayashi, C Ambrogio, T Mitsudomi Translational lung cancer research 7 (4), 487, 2018 | 69 | 2018 |
| Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma J Park, Y Kobayashi, KY Urayama, H Yamaura, Y Yatabe, T Hida PLoS One 11 (8), e0161081, 2016 | 51 | 2016 |
| Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro M Nishino, K Suda, Y Kobayashi, S Ohara, T Fujino, T Koga, M Chiba, ... Lung Cancer 126, 149-155, 2018 | 47 | 2018 |
| Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A M Chiba, Y Togashi, E Bannno, Y Kobayashi, Y Nakamura, H Hayashi, ... BMC cancer 17, 1-10, 2017 | 46 | 2017 |
| Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells Y Sesumi, K Suda, H Mizuuchi, Y Kobayashi, K Sato, M Chiba, M Shimoji, ... Lung Cancer 104, 85-90, 2017 | 44 | 2017 |
| Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies Y Kobayashi, Y Sakao, S Ito, J Park, H Kuroda, N Sakakura, N Usami, ... Journal of Thoracic Oncology 8 (8), e75-e78, 2013 | 44 | 2013 |
| EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib Y Kobayashi, T Fujino, M Nishino, T Koga, M Chiba, Y Sesumi, S Ohara, ... Journal of Thoracic Oncology 13 (5), 727-731, 2018 | 42 | 2018 |
